Drug Profile
CP 663427
Latest Information Update: 19 Jul 2006
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals; Pfizer
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 26 Jun 2002 This compound is still in active development
- 23 Jun 2000 Pfizer has merged with Warner-Lambert